证券代码：002250 证券简称：联化科技 公告编号：2023-018 联化科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 （问题征集专题页面二维码） 特此公告。 联化科技股份有限公司董事会 二〇二三年四月二十二日 出席本次说明会的人员有：公司董事长兼总裁王萍女士、高级副总裁兼董事 会秘书陈飞彪先生、财务总监薛云轩先生和独立董事俞寿云先生等。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 27日（星期四）15:00前访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题 征集专题页面。公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行 回答。 欢迎广大投资者积极参与本次网上说明会。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）定于2023年4月28日（星期五） 15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络 远程的方式举行，投资者 ...

Group 1: Investor Relations Activities - The investor relations activity was a targeted research event held on January 31, 2023, at the company's Shanghai office [1] - Participants included representatives from various financial institutions such as Tianfeng Securities and Zhongyin Securities [1] Group 2: Agricultural Protection Business - The new production capacity for the agricultural protection business is primarily located in Shandong and the UK [1] - The Jiangsu base's operational performance in 2022 was positively impacted by the global increase in agricultural product prices due to the Russia-Ukraine conflict, resulting in high utilization rates and good overall performance [1] Group 3: Pharmaceutical Projects - The pharmaceutical validation projects are progressing as planned, with some projects already completed and new validation projects being received [1] - Successful completion of these projects is expected to support growth in the pharmaceutical business in the coming years [1] Group 4: CRO Business Development - The company is expanding its CRO (Contract Research Organization) business to better meet customer needs and provide one-stop services [2] - The CRO laboratory in Shanghai is nearing completion, and the company is actively engaging with clients to explore business opportunities [2] Group 5: CDMO Business Outlook - The global agricultural terminal product market is valued at over $60 billion, with an annual growth rate of approximately 3%-5% [2] - The company focuses on serving leading agricultural enterprises and is exploring new areas such as soil health and biopesticides to ensure sustainable growth [2] Group 6: New Energy Business Development - The company has been focused on chemical synthesis and sees potential in the electronic chemicals sector as part of its future development strategy [2] - The battery chemicals project at the subsidiary Dezhou Lianhua is progressing according to plan, with installation and commissioning underway [2]

Group 1: Company Strategy and Development - The company will maintain a strategic focus on the fine chemical industry, emphasizing organic synthesis capabilities and enhancing customized services and proprietary products [1] - The company aims to promote healthy development through alliances and strategic partnerships [1] Group 2: Production and Project Updates - The Taizhou Lianhua's three fundraising projects are in normal trial production, with plans for a pilot workshop and multifunctional production workshop to commence construction, expected to be operational in the second half of 2015 [1] - The first project at Yancheng Lianhua is undergoing approval processes prior to trial production [1] - The new projects at Dezhou Lianhua are progressing, with a goal to launch three products by the end of 2014 [1] Group 3: Financial Performance and Product Insights - In 2013, the main source of new revenue and profit for Jiangsu Lianhua came from fundraising projects that commenced production that year [2] - Approximately 80% of the company's industrial revenue currently comes from pesticide intermediates, with plans to gradually increase the share of pharmaceutical intermediates in the future [2] - The company anticipates that pesticide business revenue will continue to grow, maintaining it as the primary income source for at least the next three years [2] Group 4: Environmental Investments and Challenges - The company invested over 100 million yuan in environmental facilities in 2013, which has impacted short-term performance [2] - The high environmental standards present challenges but are viewed as opportunities, with ongoing collaborations with international companies for environmental projects [2] Group 5: Sales and Revenue Generation - Taizhou Lianhua has commenced trial production, allowing for the sale of qualified products, which will generate sales revenue in the first half of the year [3]

Group 1: Project Developments - The first phase of the Texas Lianhua project has been completed on 260 acres, with the second phase currently in planning [1] - The design capacity of the phosgene facility in Texas Lianhua is set at a scale of 10,000 tons per year, with products including AKD, isocyanates, and acyl chlorides [1] - The Yancheng Lianhua pesticide project, ANBE, is currently in normal production and sales, generating expected benefits [1] Group 2: Business Improvements - The company is actively improving processes for AKD and other products, effectively reducing raw material costs and enhancing product quality [1] - The pharmaceutical intermediates business has faced slow development due to capacity, resource allocation, and market cycles, but new developments are anticipated with the completion of the Taizhou Lianhua plant and the establishment of a professional team [2] Group 3: Market Response - In response to recent significant fluctuations in the securities market, the company is formulating a plan to increase shareholding, demonstrating confidence in the capital market and the company's future [2]

Group 1: Company Development and Market Position - The company has a competitive advantage in customized chemical processing due to its strong capabilities in technology innovation, engineering construction, environmental facilities, and comprehensive management [1] - China plays a crucial role in the global chemical industry transition, with the company positioned to benefit from the outsourcing of production stages by multinational corporations [1] - The Jiangkou plant is designated as a new product incubation base, while the Taizhou plant focuses on pharmaceutical intermediates production [1][2] Group 2: Production Bases and Progress - The Taizhou plant officially commenced production in February 2015, with high-standard GMP multi-functional workshops under construction [2] - The company aims to obtain national pesticide production qualifications for its production bases in Yancheng and Jiangsu, with the first project starting trial production in March 2015 [2] - The Dezhou plant is actively developing downstream fine chemical projects to enhance production capacity [2] Group 3: Patent Expiry Impact - The company has products both under patent and nearing expiry, with varying impacts on business; generally, the price impact on original companies is significant, but the quantity impact is minimal [2] - Raw materials account for only 5%-10% of the final drug product price, indicating that price drops post-patent expiry do not primarily pressure custom service suppliers [2] Group 4: Business Strategy and Future Outlook - The trend of outsourcing pesticide and pharmaceutical intermediates in developed countries is expected to continue, providing growth opportunities for customized processing [2] - The company plans to focus on strategic alliances with major clients rather than entering formulation and terminal sales, while optimizing product structure to enhance profitability [2]

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20150807 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------| | | | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 √其他（台湾机构投资者电话会议） | | | | 参与单位名称及人员 姓名 | 国泰证券 叶岦升 南山人寿 谢尚蓉 | | 练静彤 群益投信 洪玉婷 ...

Group 1: Project Updates - The Yancheng Lianhua project received government approval for trial production in March 2015 and is currently in normal production and sales, generating expected benefits [1] - Other projects are actively seeking approval, but the timeline for trial production permits is uncertain [1] Group 2: Safety and Environmental Concerns - The company emphasizes the importance of safety in the production of phosgene, a toxic gas, and has heightened safety awareness following the Tianjin hazardous chemical explosion [1][2] - The company is committed to strict adherence to environmental laws and regulations, implementing proactive measures to reduce pollution and enhance environmental protection as a core competitive advantage [2][3] Group 3: Management and Talent Acquisition - The addition of Mr. Andreas, with experience in multinational companies, is expected to enhance the company's management in areas such as R&D, quality control, and supply chain management [2] - The company plans to recruit more international talent to further its globalization efforts [2] Group 4: Business Performance and Outlook - The pharmaceutical and intermediate business, while currently small, has a stable profit model and sufficient product pipeline for future revenue [2] - The company expects a net profit growth of 10%-30% for the first nine months of 2015 compared to the same period last year [3] - Currency fluctuations, particularly the depreciation of the RMB, are anticipated to have a positive impact on the company's performance due to its primary business being export-oriented [2]

Group 1: Company Overview and Leadership - The new executive Andreas has joined the company to enhance its pharmaceutical and pharmaceutical intermediate business development [1][2] - The company has established strong partnerships with major international pharmaceutical companies, providing opportunities for growth [2][3] Group 2: Business Growth and Strategy - The company anticipates stable growth in its pesticide and pesticide intermediate business over the next 3 to 5 years [2][4] - The company is exploring mergers and acquisitions as part of its 2020 strategic plan, focusing on both pesticide and pharmaceutical sectors [2][3] Group 3: Service Offerings and Market Position - The company provides two types of services: customized product services and new service models, including R&D services [2][4] - The company positions itself as a leading CMO (Contract Manufacturing Organization) with a strong reputation in both domestic and international markets [4][5] Group 4: Market Dynamics and Challenges - The expiration of patents in the pharmaceutical industry is expected to have a significant price impact but limited quantity impact on the market [4][5] - The company is aware of the competitive landscape and aims to leverage its experience in pesticide production to enhance its pharmaceutical capabilities [4][5] Group 5: Environmental and Safety Investments - The company invested over 100 million in environmental protection in 2014, emphasizing the importance of sustainable development [5]

联化科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------|-----------------------------------------------------|--------|--------|-------|--------|---------------------|---------------------------|---------------|----------|--------|--------| | 证券代码： \n投资者关系活动类别 | 002250 \n□特定对象调研 | | | | | □分析师会议 | 证券简称：联化科技 编号： | | 20151028 | | | | | □媒体采访 □业绩说明会 | | | | | | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | | | | □现场参观 √其他（投资者交流会--公司事业部发 ...